Osteonic: Profitable Growth and Low Multiples Alongside a 44.6% One-Year Share Price Decline

Thesis

The data supports a picture of a company that moved from losses in 2021 to consistent profits, with revenue growth of 23.2% to 40.1% a year from 2022 to 2025. Trailing return on equity is 15.5%, up from 11.8% in 2025.

The market has not rewarded this. The share price is 46.1% below its 52-week high of ₩7,740 and only about 12.4% above its low of ₩3,710. Trailing P/E is 8.5 and P/B is 1.2, well below its own year-end history and the listed peers shown.

What the data does not explain is why the price fell. No news headlines are available, so the reason for the decline cannot be determined. Free cash flow is slightly negative and borrowings exceed cash, which may be relevant. A new short-term borrowing decision was filed on 2026-10-22, and the data gives no details on its size or purpose.

Business overview

Osteonic is a KOSDAQ-listed company in the medical and precision devices sector, founded on 2012-03-09 and listed on 2018-02-22. It has 20,768,101 listed shares and a market capitalisation of about ₩86.6B. The CEO is 이동원. The data gives no description of products or customers, so this report does not cover them.

Revenue grew from ₩15.6B in 2021 to ₩45.4B in 2025. Trailing twelve-month revenue to H1 2026 is ₩51.0B.

Financial analysis

The figures below come from filed financial statements.

Revenue was ₩45.4B in 2025, up 32.6% from ₩34.2B in 2024. Operating income was ₩8.9B, a 19.5% margin. Net income was ₩7.5B. In 2024 the operating margin was 20.1%, in 2023 17.4%, in 2022 12.7% and in 2021 3.7%. Net income went from a ₩2.9B loss in 2021 to profit every year since.

Trailing twelve months to H1 2026: revenue ₩51.0B, operating income ₩9.4B (18.4% margin), net income ₩10.2B (20.0% margin) and ROE 15.5%. Net income above operating income suggests non-operating gains, but the data does not break these down.

The balance sheet shows liabilities at 57.8% of equity, cash of ₩14.3B and borrowings of ₩24.1B. Trailing free cash flow is negative at about ₩0.6M... more precisely -₩616M. Net borrowings are roughly ₩9.8B, consistent with an enterprise value of ₩96.4B against a market cap of ₩86.6B.

Valuation

At ₩4,170, Osteonic trades at 8.5 times trailing earnings, 1.2 times book value and 1.7 times sales. EV/EBITDA is not available and the dividend yield is 0.0%.

Its own year-end P/E was 17.2 in 2025, 23.9 in 2024 and 27.4 in 2023. Year-end P/B was 1.9 in 2025 and 2.3 in 2024. Current multiples are below all of these.

The listed peers shown trade at P/E of 13.2 to 71.9 and P/B of 3.3 to 6.0. These are larger companies, with market caps of ₩1.1T to ₩2.8T, so the comparison is only indicative.

The valuation model uses a 5-year discounted cash flow at a 6.9% rate, based on trailing figures to H1 2026. It gives a model estimate based on the assumptions shown of ₩6,618 per share in the base case, ₩3,693 in the bear case and ₩11,701 in the bull case. The share price is 37.0% below the base case and 12.9% above the bear case. This is not a target or a reason to buy or sell. The wide range shows how sensitive it is to assumptions.

Catalysts

• The 2026-10-22 filing on an increase in short-term borrowings could clarify how the company plans to fund its operations, though details are not in the data.
• Amended filings of the half-year report (2026-09-29) and the annual report (2026-06-26) mean the reported figures have been revised and are worth checking.
• Several 5%+ holding reports (June, August and September 2026) point to changes among large shareholders.
• Foreign investors were net buyers of about ₩154M over 20 days, though foreign ownership fell from 6.9% to 6.2% over 60 days.
• The share price rose 4.8% over the past month, a modest recovery from the 52-week low.

Risks

• The share price has fallen 44.6% in one year and 8.7% in three months, and the data does not explain the reason.
• Trailing free cash flow is negative at about ₩616M while borrowings of ₩24.1B exceed cash of ₩14.3B, and short-term borrowings are being increased.
• Trailing net income exceeds operating income, so part of the profit may not come from core operations.
• Institutions were net sellers of about ₩210M over 20 days and foreign ownership has declined.
• The model range of ₩3,693 to ₩11,701 is very wide, and the bear case is below the current price.

Closing view

Osteonic's filings show a company with growing revenue, steady profitability and a trailing ROE of 15.5%, trading at multiples well below its own recent history and the peers shown. Against that, the share price has fallen sharply for reasons not visible in the data, free cash flow is slightly negative, and borrowings are rising. The model estimate based on the assumptions shown is above the current price in the base case but below it in the bear case, so the evidence is mixed and depends on whether recent profitability can be sustained and funded.

Model estimate of fair value

Bear

₩3,693

-12%

Base

₩6,618

+59%

Bull

₩11,701

+180%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 6.9%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

• Decision on Increase in Short-Term BorrowingsOct 22, 2026
• Amended: Half-year report (Jun 2026)Sep 29, 2026
• 5%+ holding reportSep 4, 2026
• Added attachment: Half-year report (Jun 2026)Aug 14, 2026
• 5%+ holding reportAug 3, 2026
• Results of Extraordinary Shareholders' MeetingJun 26, 2026
• Amended: Annual report (Dec 2025)Jun 26, 2026
• 5%+ holding reportJun 8, 2026
• Amended attachment: Shareholders' meeting calledMay 29, 2026
• Amended attachment: Shareholders' meeting calledMay 29, 2026
• Reference Document for Proxy Solicitation of Voting RightsMay 29, 2026
• Notice of shareholders' meetingMay 29, 2026
• Daily prices up to 2026-10-23
• Financial statements, trailing 12 months as of H1 2026
• Our fair value model, statements as of TTM to H1 2026

Report history

1. Oct 24, 2026InitiationStart of coverage (reader request)Osteonic: Profitable Growth and Low Multiples Alongside a 44.6% One-Year Share Price Decline